 | |
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H18N2O |
| Molar mass | 278.355 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
AC-262536, also known asAccadrine, is a drug developed byAcadia Pharmaceuticals which acts as aselective androgen receptor modulator (SARM). Chemically it possessesendo-exo isomerism, with the endo form being the active form. It acts as apartial agonist for theandrogen receptor with aKi of 5 nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of thelevator animuscle weight increase oftestosterone, but only around 27% of its maximal effect onprostate gland weight.[1][2][3] It is ananiline SARM related toACP-105 andvosilasarm (RAD140).[4] The drug was encountered as a noveldesigner drug by at least 2020.[5]
Accadrine is not approved for any medical use by theFood and Drug Administration and is not available as a licensedpharmaceutical drug as of 2025.[6]
Accadrine isselective androgen receptor modulator (SARM), or atissue-selective mixedagonist orpartial agonist of theandrogen receptor (AR).[7][4] This receptor is thebiological target ofendogenousandrogens liketestosterone anddihydrotestosterone (DHT) and ofsyntheticanabolic steroids likenandrolone andoxandrolone.[8][9][10][11]Accadrine shows highaffinity for the AR, with a Ki value of 5 nM (relative to 29 nM for testosterone and 10 nM for DHT).[1][2][3]
